
Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Free Report) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for Inventiva in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.59) per share for the year. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Inventiva’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Inventiva’s FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.46) EPS and FY2030 earnings at ($0.09) EPS.
Several other research analysts also recently commented on IVA. Guggenheim raised their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Weiss Ratings upgraded Inventiva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.
Inventiva Stock Performance
NASDAQ IVA opened at $3.80 on Monday. Inventiva has a 1 year low of $2.82 and a 1 year high of $7.29. The company’s 50 day simple moving average is $3.73 and its two-hundred day simple moving average is $4.83.
Inventiva (NASDAQ:IVA – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million for the quarter.
Institutional Investors Weigh In On Inventiva
A number of institutional investors and hedge funds have recently bought and sold shares of IVA. Aberdeen Group plc lifted its position in Inventiva by 36.3% during the third quarter. Aberdeen Group plc now owns 3,145,711 shares of the company’s stock valued at $11,608,000 after purchasing an additional 837,938 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock worth $332,000 after buying an additional 5,857 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Inventiva by 78.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock worth $142,000 after buying an additional 17,000 shares in the last quarter. Platt Investment Counsel LLC bought a new position in shares of Inventiva in the 3rd quarter worth $45,000. Finally, Engineers Gate Manager LP increased its holdings in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after buying an additional 43,280 shares during the last quarter. 19.06% of the stock is owned by hedge funds and other institutional investors.
About Inventiva
Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.
Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.
Read More
- Five stocks we like better than Inventiva
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
